×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
SGMO – sangamo therapeutics, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
SGMO
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
3/18
11:42 am
sgmo
Sangamo Therapeutics, Inc. (NASDAQ: SGMO) had its "sector perform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $2.00 price target on the stock.
Low
Report
Sangamo Therapeutics, Inc. (NASDAQ: SGMO) had its "sector perform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $2.00 price target on the stock.
3/17
04:49 pm
sgmo
Sangamo Therapeutics, Inc. 2024 Q4 - Results - Earnings Call Presentation [Seeking Alpha]
High
Report
Sangamo Therapeutics, Inc. 2024 Q4 - Results - Earnings Call Presentation [Seeking Alpha]
3/17
04:01 pm
sgmo
Sangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2024 Financial Results
High
Report
Sangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2024 Financial Results
3/6
04:05 pm
sgmo
Sangamo Therapeutics Announces Fourth Quarter and Full Year 2024 Earnings Call and Participation in Upcoming Investor Conference
High
Report
Sangamo Therapeutics Announces Fourth Quarter and Full Year 2024 Earnings Call and Participation in Upcoming Investor Conference
2/6
08:37 am
sgmo
Sangamo Therapeutics Announces Updated Phase 1/2 STAAR Study Data in Fabry Disease Showing Sustained Benefit, Improvements in Kidney Function and Favorable Safety Profile [Yahoo! Finance]
Medium
Report
Sangamo Therapeutics Announces Updated Phase 1/2 STAAR Study Data in Fabry Disease Showing Sustained Benefit, Improvements in Kidney Function and Favorable Safety Profile [Yahoo! Finance]
2/6
08:05 am
sgmo
Sangamo Therapeutics Announces Updated Phase 1/2 STAAR Study Data in Fabry Disease Showing Sustained Benefit, Improvements in Kidney Function and Favorable Safety Profile
Low
Report
Sangamo Therapeutics Announces Updated Phase 1/2 STAAR Study Data in Fabry Disease Showing Sustained Benefit, Improvements in Kidney Function and Favorable Safety Profile
2/1
10:00 am
sgmo
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sangamo Therapeutics, Inc. - SGMO
Medium
Report
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sangamo Therapeutics, Inc. - SGMO
1/30
12:00 pm
sgmo
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sangamo Therapeutics, Inc. - SGMO
Medium
Report
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sangamo Therapeutics, Inc. - SGMO
Date
Time
Symbol
Company Name
Action
%Chg
3/17/2025
04:01 pm
sgmo
sangamo therapeutics, inc.
MISS
Report
-17.8%
sangamo therapeutics, inc.
3/17/2025
04:01 pm
sgmo
sangamo therapeutics, inc.
MISS
Report
-17.8%
sangamo therapeutics, inc.
3/17/2025
04:01 pm
sgmo
sangamo therapeutics, inc.
MISS
Report
-17.8%
sangamo therapeutics, inc.
3/17/2025
04:01 pm
sgmo
sangamo therapeutics, inc.
MISS
Report
-17.8%
sangamo therapeutics, inc.
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
3/17
04:06 pm
sgmo
Form 10-K SANGAMO THERAPEUTICS, For: Dec 31
High
Report
Form 10-K SANGAMO THERAPEUTICS, For: Dec 31
3/17
04:02 pm
sgmo
Form 8-K SANGAMO THERAPEUTICS, For: Mar 17
High
Report
Form 8-K SANGAMO THERAPEUTICS, For: Mar 17
2/26
05:33 pm
sgmo
Form 4 SANGAMO THERAPEUTICS, For: Feb 24 Filed by: Davis Gregory D
Low
Report
Form 4 SANGAMO THERAPEUTICS, For: Feb 24 Filed by: Davis Gregory D
2/26
05:33 pm
sgmo
Form 4 SANGAMO THERAPEUTICS, For: Feb 24 Filed by: Dubois-Stringfellow Nathalie
Low
Report
Form 4 SANGAMO THERAPEUTICS, For: Feb 24 Filed by: Dubois-Stringfellow Nathalie
2/26
05:32 pm
sgmo
Form 4 SANGAMO THERAPEUTICS, For: Feb 24 Filed by: Willoughby Scott B.
Low
Report
Form 4 SANGAMO THERAPEUTICS, For: Feb 24 Filed by: Willoughby Scott B.
2/26
05:31 pm
sgmo
Form 4 SANGAMO THERAPEUTICS, For: Feb 24 Filed by: Duraibabu Prathyusha
Low
Report
Form 4 SANGAMO THERAPEUTICS, For: Feb 24 Filed by: Duraibabu Prathyusha
2/26
05:30 pm
sgmo
Form 4 SANGAMO THERAPEUTICS, For: Feb 24 Filed by: Macrae Sandy
Low
Report
Form 4 SANGAMO THERAPEUTICS, For: Feb 24 Filed by: Macrae Sandy
2/6
08:14 am
sgmo
Form 8-K SANGAMO THERAPEUTICS, For: Feb 06
Medium
Report
Form 8-K SANGAMO THERAPEUTICS, For: Feb 06
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
2/27
Biogen and Sangamo Announce Global Collaboration to Develop Gene Regulation Therapies for Alzheimer’s, Parkinson’s, Neuromuscular, and Other Neurological Diseases
33.3%
4/2 Form DEF 14A SANGAMO THERAPEUTICS, For: May 18 8.8%
4/17 Form 8-K SANGAMO THERAPEUTICS, For: Apr 13 8.6%
3/16 Sangamo's Partnership With Biogen Is Only One Big Pharma Partnership Based Off Of Pipeline [Seeking Alpha] 8.2%
3/18 Form 4 SANGAMO THERAPEUTICS, For: Mar 16 Filed by: DILLY STEPHEN GEORGE 7.5%
4/9 Sangamo Announces Closing of Biogen Collaboration Agreement 6.9%
12/23 Form 8-K SANGAMO THERAPEUTICS, For: Dec 17 6.4%
4/28 Form 4 SANGAMO THERAPEUTICS, For: Apr 25 Filed by: Duraibabu Prathyusha 6.0%
5/15 Sangamo Therapeutics Announces Presentations At Upcoming Scientific, Medical And Investor Conferences 5.9%
11/8 Sangamo Therapeutics Announces New Scientific Advisory Board 5.5%
4/2 Form DEF 14A SANGAMO THERAPEUTICS, For: May 18 8.8%
4/17 Form 8-K SANGAMO THERAPEUTICS, For: Apr 13 8.6%
3/16 Sangamo's Partnership With Biogen Is Only One Big Pharma Partnership Based Off Of Pipeline [Seeking Alpha] 8.2%
3/18 Form 4 SANGAMO THERAPEUTICS, For: Mar 16 Filed by: DILLY STEPHEN GEORGE 7.5%
4/9 Sangamo Announces Closing of Biogen Collaboration Agreement 6.9%
12/23 Form 8-K SANGAMO THERAPEUTICS, For: Dec 17 6.4%
4/28 Form 4 SANGAMO THERAPEUTICS, For: Apr 25 Filed by: Duraibabu Prathyusha 6.0%
5/15 Sangamo Therapeutics Announces Presentations At Upcoming Scientific, Medical And Investor Conferences 5.9%
11/8 Sangamo Therapeutics Announces New Scientific Advisory Board 5.5%
TOP News Decliners
3/14
Sangamo Therapeutics Inc (NASDAQ: SGMO) was downgraded by analysts at BidaskClub from a "sell" rating to a "strong sell" rating.
-25.2%
12/9 Sangamo Therapeutics Inc (NASDAQ: SGMO) had its "buy" rating re-affirmed by analysts at Cowen Inc. -17.4%
5/8 Q1/2019 3/31/2019 EPS -0.410 ZacksConsensus -0.270 ActVsEst (0.140) - Miss -14.8%
2/28 Q4/2019 12/31/2019 EPS 0.040 ZacksConsensus -0.310 ActVsEst 0.350 - Beat -8.4%
8/7 Sangamo Therapeutics Reports Second Quarter 2019 Financial Results -6.1%
3/2 AbbVie Is A Notable Coronavirus Responder — But Is ABBV Stock A Buy? [Investor's Business Daily] -6.0%
4/21 Mogrify and Sangamo Announce Collaboration and Exclusive License Agreement for Mogrify’s iPSC- and ESC-Derived Regulatory T Cells -5.9%
4/2 Sangamo Therapeutics Inc (NASDAQ: SGMO) was upgraded by analysts at ValuEngine from a "hold" rating to a "buy" rating. -5.3%
1/25 Sangamo Therapeutics Inc (NASDAQ: SGMO) was downgraded by analysts at BidaskClub from a "sell" rating to a "strong sell" rating. -4.9%
9/30 Sangamo Therapeutics Appoints Bettina M. Cockroft, MD, MBA, as Senior Vice President and Chief Medical Officer -4.8%
12/9 Sangamo Therapeutics Inc (NASDAQ: SGMO) had its "buy" rating re-affirmed by analysts at Cowen Inc. -17.4%
5/8 Q1/2019 3/31/2019 EPS -0.410 ZacksConsensus -0.270 ActVsEst (0.140) - Miss -14.8%
2/28 Q4/2019 12/31/2019 EPS 0.040 ZacksConsensus -0.310 ActVsEst 0.350 - Beat -8.4%
8/7 Sangamo Therapeutics Reports Second Quarter 2019 Financial Results -6.1%
3/2 AbbVie Is A Notable Coronavirus Responder — But Is ABBV Stock A Buy? [Investor's Business Daily] -6.0%
4/21 Mogrify and Sangamo Announce Collaboration and Exclusive License Agreement for Mogrify’s iPSC- and ESC-Derived Regulatory T Cells -5.9%
4/2 Sangamo Therapeutics Inc (NASDAQ: SGMO) was upgraded by analysts at ValuEngine from a "hold" rating to a "buy" rating. -5.3%
1/25 Sangamo Therapeutics Inc (NASDAQ: SGMO) was downgraded by analysts at BidaskClub from a "sell" rating to a "strong sell" rating. -4.9%
9/30 Sangamo Therapeutics Appoints Bettina M. Cockroft, MD, MBA, as Senior Vice President and Chief Medical Officer -4.8%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: